Definition
A competitive serotonin type 3 receptor antagonist. It is effective in the treatment of nausea and vomiting caused by cytotoxic chemotherapy drugs, including cisplatin, and has reported anxiolytic and neuroleptic properties.
Ondansetron is a well tolerated drug with few side effects. Headache, constipation, and dizziness are the most commonly reported side effects associated with its use. There have been no significant drug interactions reported with this drugs use. It is broken down by the hepatic cytochrome P450 system and it has little effect on the metabolism of other drugs broken down by this system; Ondansetron is a serotonin 5-HT3 receptor antagonist used mainly to treat nausea and vomiting following chemotherapy. Its effects are thought to be on both peripheral and central nerves. One part is to reduce the activity of the vagus nerve, which is a nerve that activates the vomiting center in the medulla oblongata, the other is a blockage of serotonin receptors in the chemoreceptor trigger zone. It does not have much effect on vomiting due to motion sickness. This drug does not have any effect on dopamine receptors or muscarinic receptors; A competitive serotonin type 3 receptor antagonist. It is effective in the treatment of nausea and vomiting caused by cytotoxic chemotherapy drugs, including cisplatin, and has reported anxiolytic and neuroleptic properties; Ondansetron (INN) is a serotonin 5-HT3 receptor antagonist used mainly to treat nausea and vomiting following chemotherapy. Its effects are thought to be on both peripheral and central nerves. One part is to reduce the activity of the vagus nerve, which is a nerve that activates the vomiting center in the medulla oblongata, the other is a blockage of serotonin receptors in the chemoreceptor trigger zone. It does not have much effect on vomiting due to motion sickness. This drug does not have any effect on dopamine receptors or muscarinic receptors. [HMDB]
Description
Ondansetron is a well tolerated drug with few side effects. Headache, constipation, and dizziness are the most commonly reported side effects associated with its use. There have been no significant drug interactions reported with this drugs use. It is broken down by the hepatic cytochrome P450 system and it has little effect on the metabolism of other drugs broken down by this system; Ondansetron is a serotonin 5-HT3 receptor antagonist used mainly to treat nausea and vomiting following chemotherapy. Its effects are thought to be on both peripheral and central nerves. One part is to reduce the activity of the vagus nerve, which is a nerve that activates the vomiting center in the medulla oblongata, the other is a blockage of serotonin receptors in the chemoreceptor trigger zone. It does not have much effect on vomiting due to motion sickness. This drug does not have any effect on dopamine receptors or muscarinic receptors; A competitive serotonin type 3 receptor antagonist. It is effective in the treatment of nausea and vomiting caused by cytotoxic chemotherapy drugs, including cisplatin, and has reported anxiolytic and neuroleptic properties; Ondansetron (INN) is a serotonin 5-HT3 receptor antagonist used mainly to treat nausea and vomiting following chemotherapy. Its effects are thought to be on both peripheral and central nerves. One part is to reduce the activity of the vagus nerve, which is a nerve that activates the vomiting center in the medulla oblongata, the other is a blockage of serotonin receptors in the chemoreceptor trigger zone. It does not have much effect on vomiting due to motion sickness. This drug does not have any effect on dopamine receptors or muscarinic receptors.
Top Gene Interactions
Related Pathways
General Information
- Metabolism: Hepatic Half Life: 5.7 hours
- Uses/Sources: For the prevention of nausea and vomiting associated with emetogenic cancer chemotherapy, postoperation, and radiation. Also used for the treatment of postoperative nausea and vomiting.
- Symptoms: Low blood pressure and fainting, sudden blindness, severe constipation
- Treatment: There is no specific antidote for ondansetron overdose. Patients should be managed with appropriate supportive therapy. (L1712)
- Route of Exposure: Ondansetron is well absorbed after oral administration and undergoes limited first-pass metabolism.
Mechanism of Action
Target Name | Mechanism of Action | References |
---|---|---|
Potassium voltage-gated channel subfamily H member 2 Cytochrome P450 3A4 Neuronal acetylcholine receptor subunit alpha-4 5-hydroxytryptamine receptor 1A Mu-type opioid receptor 5-hydroxytryptamine receptor 1B 5-hydroxytryptamine receptor 4 Solute carrier family 22 member 1 Solute carrier family 22 member 2 Multidrug and toxin extrusion protein 1 Serotonin Receptors Multidrug and toxin extrusion protein 2 Solute carrier family 22 member 3 |
18448342 23241029 2164935 21599003 15911273 12873512 8230119 11212100 15050614 20889341 2342053 |
|
5-hydroxytryptamine receptor 3A 5-hydroxytryptamine receptor 6 |
Ondansetron is a selective serotonin 5-HT3 receptor antagonist. The serotonin 5-HT3 receptors are located on the nerve terminals of the vagus in the periphery and centrally in the chemoreceptor trigger zone of the area postrema. It is thought that chemotherapeutic agents produce nausea and vomiting by releasing serotonin from the enterochromaffin cells of the small intestine, and that the released serotonin then activates 5-HT3 receptors located on vagal efferents to initiate the vomiting reflex. Therefore Ondansetron works by blocking the reception of serotonin at these 5-HT3 receptors. |
12032025 10517265 11752352 2145434 10065930 2213824 11919526 21486038 11763467 20889341 11972287 |
Ondansetron Interacts with Diseases
Disease | Inference Score | References/Inference Genes |
Sexual Dysfunctions, Psychological | 6.46 |
|
Drug Metabolism, Poor, CYP2D6-Related | 5.69 | |
Amphetamine-Related Disorders | 5.56 | |
Ige Responsiveness, Atopic | 5.1 |
|
Kidney disease | 4.94 |
|
Autism | 4.48 |
|
Morphine Dependence | 4.47 |
|
Acute kidney injury | 4.38 |
|
Drug-Related Side Effects and Adverse Reactions | 4.22 | |
Focal segmental glomerulosclerosis | 4.0 |
|
Manganese Poisoning | 3.99 |
|
Autism spectrum disorder | 3.89 |
|
Occupational Diseases | 3.69 |
|
Splenic Diseases | 3.63 |
|
Intellectual Disability | 3.61 |
|
Porphyria Cutanea Tarda | 3.55 |
|
Hypotension | 3.54 |
|
Learning Disorders | 3.51 |
|
Epilepsy | 3.47 |
|
Proteinuria | 3.42 |
|